Emzor Raises Naira Five-Year Debt At 19%: Nigerian Corporate Funding Costs Stay Elevated

Emzor Pharma Funding SPV PLC has listed a ₦26.70 billion, five-year Series 1 fixed-rate bond on FMDQ Exchange at a 19.00% coupon, equivalent to approximately US$19.8 million. The issuance sits within a ₦40 billion bond programme and provides a concrete example of Nigerian private-sector access to longer-duration domestic funding despite a high nominal cost of capital. Proceeds are earmarked for working capital and manufacturing expansion, including completion of Emzor Pharmaceutical Industries’ antimalarial active pharmaceutical ingredient facility in Ogun State.

For Nigerian fixed income, the transaction extends corporate credit supply into the five-year segment while embedding a substantial funding premium for a private issuer. The 19% coupon is relevant to local-rate formation: if elevated domestic funding costs persist, refinancing and debt-service burdens remain material for corporates seeking to finance capacity expansion in naira. The bond also broadens the investable universe beyond sovereign and financial-sector exposure, although its senior unsecured structure leaves credit analysis distinct from sovereign risk analysis.

The industrial use of proceeds creates a specific import-substitution channel. Completing local antimalarial API production could reduce dependence on imported pharmaceutical inputs over time, but the immediate market relevance is the ability to fund that capacity through Nigeria’s domestic bond market at a fixed rate. This contrasts with a purely working-capital transaction by linking issuance to productive investment, while the coupon still demonstrates the cost imposed on private-sector balance sheets.

The next reference point is whether other Nigerian corporates can access comparable maturities and pricing under the same domestic-rate conditions. Broader issuance would strengthen evidence that the local corporate-credit market is deepening; limited follow-through would leave Emzor as an important but isolated example of longer-term market access.